MyoScreenTM, a High-Content Screening Platform Enabling Muscle Drug Discovery

novembre 10, 2025

MyoScreen™ is an improvement of current in vitro muscle models, enabling a more predictive screening strategy for preclinical selection of the most efficacious candidates earlier in the discovery pipeline process.

MyoScreen™ allows us to reproduce the patient’s muscle tissue from a simple biopsy. These muscle cells, which mimic the morphology, contractile and metabolic functions of the muscle, are seeded in micropatterned plates (up to 10,000 mini-muscles per plate) to analyze them, expose them to various treatments, then detect, understand and evaluate the mechanism of action of drug candidates.

Successfully applied to:

🧬 Genetic inherited muscular diseases (DMD, DM1, FSHD…)

🧠 Other neuromuscular disorders

⚡ Metabolic disorders (muscle weakness and wasting, obesity, diabetes)

MyoScreen™ platform brings new prospects for drug discovery related to muscle health, facilitating a predictive research strategy for identifying and validating novel targets, and supporting preclinical development to select innovative drug candidates for next-generation therapies.

🔗 Check out here!